Neumora Q1 net loss $53.7M; navacaprant Phase 3 MDD data on track for Q4 2024; NMRA-266 clinical hold with FDA

Neumora Therapeutics, Inc.

2024-Q1 EPS reported -$0.34

Net loss of $53.7M in Q1 2024 vs $35.6M in Q1 2023; R&D expense $45.8M, G&A $14.3M.
Cash, cash equivalents and marketable securities of $423.0M; expected to fund operations into 2026.
Topline Phase 3 data from navacaprant KOASTAL-1 in MDD expected Q4 2024; Phase 2 bipolar depression trial to start Q2 2024.
NMRA-511 Phase 1 complete; Phase 1b in Alzheimer's agitation to start Q2 2024 with data in 2025.
FDA placed clinical hold on NMRA-266 Phase 1 study; company working to resolve; additional M4 PAM IND expected 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $53.7 million.

Period: the first quarter ended March 31, 2024
Net income: net loss of $53.7 million
Result: reported results

Exact text from the filing

announced its financial results for the first quarter ended March 31, 2024

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.